ATS Announces that BI is First Donor of COVID-19 Fund | Boehringer Ingelheim US
American Thoracic Society Announces that Boehringer Ingelheim is the first donor of its COVID‐19 Crisis Fund
Search
Life forward - Boehringer Ingelheim unveils its evolved company brand
Life forward - Boehringer Ingelheim unveils its evolved company brand
A day of giving back at Pegasus Therapeutic Riding
Take a look at our volunteer day spent refreshing a farm committed to equine therapy.
Digital solutions save lives
Digital solutions save lives
Europe’s Largest Initiative Launches to Accelerate Therapy Development for COVID-19 and Future Coronavirus Threats
Europe’s Largest Initiative Launches to Accelerate Therapy Development for COVID-19 and Future Coronavirus Threats
Boehringer Ingelheim Announces U.S. Country Managing Director Jean-Michel Boers Appointed to PhRMA Board of Directors
Boehringer Ingelheim Announces U.S. Country Managing Director Jean-Michel Boers Appointed to PhRMA Board of Directors
200 employees make a difference with record-breaking volunteer efforts
200 employees make a difference with record-breaking volunteer efforts
Boehringer Ingelheim hosts Governor Lamont press conference at our Apple Blossom learning center to support more on-site childcare options in Connecticut
Read about Connecticut Governor Ned Lamont and his administration’s visit to our U.S. headquarters in Ridgefield to tour our Apple Blossom Children’s Learning Center, to express the need for more childcare options for local communities and businesses.
Saving Stroke Patients around the world
Suffering a stroke is one of the most devastating medical emergencies that can happen to a person. Over 15 million people worldwide suffer a stroke every year.
Bigger Role in Ensuring Food Security | Boehringer Ingelheim US
As the population of the earth grows, animal health becomes fundamental in ensuring well-being and the global protein supply. Click here to find out more.
Boehringer Ingelheim Completes Plant Expansion After $76 Million Georgia Investment
Boehringer Ingelheim Completes Plant Expansion After $76 Million Georgia Investment
Patients with a rare and aggressive form of liposarcoma need treatment advances
Patients with a rare and aggressive form of liposarcoma need treatment advances
Boehringer Ingelheim Celebrates 50th Anniversary in the U.S. by Committing Up to $450,000 to Nonprofit Partners
Boehringer Ingelheim Celebrates 50th Anniversary in the U.S. by Committing Up to $450,000 to Nonprofit Partners
Boehringer Ingelheim launches vaccine to protect poultry from three diseases
Boehringer Ingelheim launches vaccine to protect poultry from three diseases
Boehringer Ingelheim expands free telemedicine platform to connect veterinarians and pet owners at a time of social distancing
Boehringer Ingelheim expands free telemedicine platform to connect veterinarians and pet owners at a time of social distancing
Embracing Differences: Our journey to diversity, equity, and inclusion
Embracing Differences: Our journey to diversity, equity, and inclusion
First Half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline
First Half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline
New Documentary Highlights Ranch’s Commitment to Cattle Health
New Documentary Highlights Ranch’s Commitment to Cattle Health
Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center
Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center
Cyltezo® (adalimumab-adbm) Patent Litigation Resolution| BI US
Read more about Boehringer Ingelheim's CYLTEZO patent litigation resolution, meaning greater access to the treatment for patients across the USA.
Boehringer Ingelheim and Gubra announce new collaboration to develop anti-obesity peptide poly-agonists
Boehringer Ingelheim and Gubra announce new collaboration to develop anti-obesity peptide poly-agonists
Boehringer Ingelheim Advances Novel Bi-specific TRAILR2/CDH17 Antibody to Phase 1 Clinical Trial for Patients Living with Gastrointestinal Cancers
Boehringer Ingelheim Advances Novel Bi-specific TRAILR2/CDH17 Antibody to Phase 1 Clinical Trial for Patients Living with Gastrointestinal Cancers
Yew Looi Liew Named President of U.S. Human Pharma for Boehringer Ingelheim Pharmaceuticals, Inc.
Yew Looi Liew Named President of U.S. Human Pharma for Boehringer Ingelheim Pharmaceuticals, Inc.
Queen Latifah and Bernie Williams star in Boehringer Ingelheim’s “Beyond Breathless” documentary on A&E
Queen Latifah and Bernie Williams star
Boehringer Ingelheim Animal Health Announces U.S. Leadership Transition
Boehringer Ingelheim Animal Health Announces U.S. Leadership Transition